JPS60228490A - Organogermanium compound - Google Patents
Organogermanium compoundInfo
- Publication number
- JPS60228490A JPS60228490A JP59083831A JP8383184A JPS60228490A JP S60228490 A JPS60228490 A JP S60228490A JP 59083831 A JP59083831 A JP 59083831A JP 8383184 A JP8383184 A JP 8383184A JP S60228490 A JPS60228490 A JP S60228490A
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- compound
- organic germanium
- germanium compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 Organogermanium compound Chemical class 0.000 title description 13
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 30
- 150000002291 germanium compounds Chemical class 0.000 claims abstract description 28
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 18
- 125000003277 amino group Chemical group 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 14
- 125000003545 alkoxy group Chemical group 0.000 claims description 11
- 125000004432 carbon atom Chemical group C* 0.000 claims description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 7
- 125000004414 alkyl thio group Chemical group 0.000 claims description 7
- 125000000542 sulfonic acid group Chemical group 0.000 claims description 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 abstract description 18
- 150000001875 compounds Chemical class 0.000 abstract description 12
- 230000018044 dehydration Effects 0.000 abstract description 5
- 238000006297 dehydration reaction Methods 0.000 abstract description 5
- 238000002360 preparation method Methods 0.000 abstract description 4
- 125000004103 aminoalkyl group Chemical group 0.000 abstract description 3
- ZRYZBQLXDKPBDU-UHFFFAOYSA-N 4-bromobenzaldehyde Chemical compound BrC1=CC=C(C=O)C=C1 ZRYZBQLXDKPBDU-UHFFFAOYSA-N 0.000 abstract description 2
- 150000003935 benzaldehydes Chemical class 0.000 abstract description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzenecarboxaldehyde Natural products O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 abstract description 2
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 abstract description 2
- 239000002904 solvent Substances 0.000 abstract description 2
- 230000003327 cancerostatic effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 11
- 125000001424 substituent group Chemical group 0.000 description 11
- 238000010521 absorption reaction Methods 0.000 description 10
- 125000005843 halogen group Chemical group 0.000 description 9
- 239000007788 liquid Substances 0.000 description 8
- 230000001093 anti-cancer Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000000862 absorption spectrum Methods 0.000 description 6
- 238000009835 boiling Methods 0.000 description 6
- 238000000921 elemental analysis Methods 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 5
- 206010003445 Ascites Diseases 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 229910052732 germanium Inorganic materials 0.000 description 4
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 4
- 238000001819 mass spectrum Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 4
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000001793 charged compounds Chemical class 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- BUZYGTVTZYSBCU-UHFFFAOYSA-N 1-(4-chlorophenyl)ethanone Chemical compound CC(=O)C1=CC=C(Cl)C=C1 BUZYGTVTZYSBCU-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical class CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical group CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- JQVDAXLFBXTEQA-UHFFFAOYSA-N dibutylamine Chemical group CCCCNCCCC JQVDAXLFBXTEQA-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical group II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000000082 organogermanium group Chemical group 0.000 description 1
- 150000002902 organometallic compounds Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【発明の詳細な説明】
本発明は、一般式
(但し、Rはアルキル基;nは正の整数:Aは水素原子
又はアルキル基Hz、x及び2はそれぞれ同種又は異種
の水素原子、ハロゲン原子、アルキル基、アルコキシ基
、ヒドロキシ基、シアノ基、ニトロ基、アルキルチオ基
、アルコキシカルボニル基、カルボキシル基及びその塩
型基、スルホン酸基及びその塩型基、ジ(アルキル)ア
ミノ基、又はジ()\ロアルキル)アミノ基で、!及び
Yは隣接した炭素原子に置換したで示される有機ゲルマ
ニウム化合物、及び咳ゲル1ニウム化合物を有効成分と
する制癌剤を提供するものである。Detailed Description of the Invention The present invention is based on the general formula (wherein R is an alkyl group; n is a positive integer; A is a hydrogen atom or an alkyl group Hz; x and 2 are the same or different hydrogen atoms, halogen atoms, respectively; , alkyl group, alkoxy group, hydroxy group, cyano group, nitro group, alkylthio group, alkoxycarbonyl group, carboxyl group and its salt type group, sulfonic acid group and its salt type group, di(alkyl)amino group, or di( ) \roalkyl) amino group,! The present invention provides an anticancer agent containing an organic germanium compound in which and Y is substituted with an adjacent carbon atom, and a cough gel mononium compound as active ingredients.
近年、有機ゲルマニウム化合物の薬理活性、特に抗腫瘍
性、免疫賦活性、降血圧作用、抗炎症作用などが著しく
注目されている。In recent years, the pharmacological activities of organic germanium compounds, particularly their antitumor properties, immunostimulatory effects, antihypertensive effects, and anti-inflammatory effects, have attracted much attention.
本発明者らは長年有機金属化合物、特に有機ゲルマニウ
ム化合物の合成や生理活性について鋭意研究を行なって
きた。その結果、下記一般(但し、Rはアルキル基;n
は正の整数;Aは水素原子又はアルキル基:X、!及び
2はそれぞれ同種又は異種の水素原子、)・ロゲ/原子
、アルキル基、アルコキシ基、ヒドロキシ基、シアノ基
、ニトロ基、アルキルチオ基、アルコキシカルボニル基
、カルボキシル基及びその塩型基、スルホン酸基及びそ
の塩型基、ジ(アルキル)アミノ基、又はジ(ハロアル
キル)アミノ基で、!及び!は隣接した炭素原子に置換
したつで表わされる基であってもよい。)
で示される新規な有機ゲルマニウム化合物の製法を確立
し、また該有機ゲルマニウム化合物が優れた生理活性、
殊に制癌活性を有することを見い出し、本発明を完成し
提案するに至った。The present inventors have been conducting intensive research on the synthesis and physiological activities of organometallic compounds, particularly organogermanium compounds, for many years. As a result, the following general (where R is an alkyl group; n
is a positive integer; A is a hydrogen atom or an alkyl group: X,! and 2 are hydrogen atoms of the same or different types, respectively.) Rogge/atom, alkyl group, alkoxy group, hydroxy group, cyano group, nitro group, alkylthio group, alkoxycarbonyl group, carboxyl group and its salt type group, sulfonic acid group and its salt type group, di(alkyl)amino group, or di(haloalkyl)amino group,! as well as! may be a group represented by substituted with adjacent carbon atoms. ) has been established, and the organic germanium compound has excellent physiological activity,
They have found that it has particularly anticancer activity, and have completed and proposed the present invention.
即ち、本発明は、一般式
(但し、Rはアルキル基;nは正の整数;ムは水素原子
又はアルキル基:X、!及び2はそれぞれ同種又は異種
の水素原子、ハロゲン原子、アルキル基、アルコキシ基
、ヒドロキシ基、シアノ基、ニド四基、アルキルチオ基
、アルコキシカルボニル基、カルボキシル基及びその塩
型基、スルホン酸基及びその塩型基、ジ(アルキル)ア
ミン基、又はジ(/10アルキル)アミノ基で、X及び
!は隣接した炭素原子に置換した○で表わされる基であ
ってもよい。)
で示される有機ゲルマニウム化合物、及び咳有機ゲルマ
ニウム化合物を有効成分とする制癌剤を提供するもので
ある。That is, the present invention is based on the general formula (where R is an alkyl group; n is a positive integer; M is a hydrogen atom or an alkyl group; Alkoxy group, hydroxy group, cyano group, nido tetragroup, alkylthio group, alkoxycarbonyl group, carboxyl group and its salt type group, sulfonic acid group and its salt type group, di(alkyl)amine group, or di(/10 alkyl ) In the amino group, X and ! may be a group represented by ○ substituted with adjacent carbon atoms. It is.
本発明の有機ゲルマニウム化合物は上記一般式で示され
る化合物である。一般式中、Rはアルキル基であれば特
に限定されるものではないが、一般には炭素原子数1〜
4の直鎖状もしくは分校状低級アルキル基が工業的入手
の容易さから好適に使用される。異体的には、メチル基
、エチル基、n−プμピル基、lll0−グロビル基、
−+CH2七〕 のnは正の整数であれば特に限定され
ないが、原料の入手の容易さや取扱いの容易さ等からn
は1〜12好ましくは1〜6が好適である。上記アルキ
レン基として特に好適に使用されるものを具体的に例示
すると例えば、−aw@−、−0111011101!
l−1−QiIlolllORlcal−1−OH@O
TE、OH@OH雪OH雪−、−011鵞QTI@CJ
H@CJH@OK雪C3H暑−1fOIhi などであ
る。また一般式中入で示さ“れるアルキル基は、特に限
定されないが、一般にはメ′チル基、エチル基等の低級
アルキル基が原料の入手の容易さ等から好適に使用され
る・また、前記一般゛式中の置換基X、Y、ZK於いて
、X、Y、Zがすべて水素原子の場合は非置換体であり
、−置換体の場合の置換基を!、二置換体の場合の置換
基をI、!、三置換体の場合をx、y、zとすると、X
としては、ハロゲン原子、アルキル基、アルコキシ基、
ヒドロキシ基・、シアノ基、ニトロ基、アルキルチオ基
、アルコキシカルボニル基、カルボキシル基及びその塩
型基、スルホ/酸基及びその塩型基、ジ(アルキル)ア
ミノ基、ジ(ハロアルキル)アミノ基等が好適である。The organic germanium compound of the present invention is a compound represented by the above general formula. In the general formula, R is not particularly limited as long as it is an alkyl group, but generally has 1 to 1 carbon atoms.
The linear or branched lower alkyl group of No. 4 is preferably used because of its industrial ease of availability. Isomorphically, methyl group, ethyl group, n-propyl group, lll0-globyl group,
-+CH27] n is not particularly limited as long as it is a positive integer, but n is
is preferably 1 to 12, preferably 1 to 6. Specific examples of particularly preferably used alkylene groups include -aw@-, -0111011101!
l-1-QiIlolllORlcal-1-OH@O
TE, OH@OH snow OH snow-, -011 Goose QTI@CJ
H@CJH@OK snow C3H heat-1fOIhi etc. In addition, the alkyl group represented by the general formula is not particularly limited, but lower alkyl groups such as methyl and ethyl groups are generally preferably used from the viewpoint of easy availability of raw materials. In the substituents X, Y, and ZK in the general formula, if X, Y, and Z are all hydrogen atoms, it is an unsubstituted product, a substituent in a -substituted product, and a disubstituted product! If the substituent is I, !, and the trisubstituted case is x, y, z, then
Examples include halogen atoms, alkyl groups, alkoxy groups,
Hydroxy group, cyano group, nitro group, alkylthio group, alkoxycarbonyl group, carboxyl group and its salt type group, sulfo/acid group and its salt type group, di(alkyl)amino group, di(haloalkyl)amino group, etc. suitable.
またIとしては、ハロゲン原子、アルキル基、また前記
一般式中のx1Y及び2はそれぞれ同種又は異種の水素
原子、ハロゲン原子、アルキル基、アルコキシ基、ヒド
ロキシ基、シアン基、ニトロ基、アルキルチオ基、アル
コキシカルボニル基、カルボキシル基及びその塩型基、
スルホン酸基及びその塩型基、シ(アルキル)アミノ基
、又はジ(ハロアルキル)アミノ基で、X及びYは隣接
した炭素原子に置換したつで表わされる基であってもよ
い。上記X、Y及び2が全て水素原子のときは非置換体
であるがその他のケースは一置換体、二置換体及び三置
換体の形をとりうる。該置換基は前記種々の基をとり5
るが一般に置換基の数が多くなるに従ってその製造が複
雑になる。I is a halogen atom, an alkyl group, and x1Y and 2 in the above general formula are the same or different hydrogen atoms, halogen atoms, alkyl groups, alkoxy groups, hydroxy groups, cyan groups, nitro groups, alkylthio groups, Alkoxycarbonyl group, carboxyl group and its salt type group,
The group may be a sulfonic acid group or its salt type group, a cy(alkyl)amino group, or a di(haloalkyl)amino group, in which X and Y are substituted on adjacent carbon atoms. When all of the above X, Y and 2 are hydrogen atoms, it is an unsubstituted product, but in other cases it can take the form of a monosubstituted, disubstituted or trisubstituted product. The substituents include the various groups mentioned above.
However, in general, as the number of substituents increases, the production becomes more complicated.
一般に工業的には前記置換基から選ばれた一置換体が最
も広く使用され一゛るが、二置換体のものは前記置換基
から選ばれた1種の置換基と二置換基としては特にハロ
ゲン原子、アルキル基、アルコキシ基、ヒドロキシ基等
が工業的に好適であり、更に三置換体としての置換基は
上記二置換基体の置換基の選択に加えて特にハロゲン原
子、アルキル基、及びアルコキシ基等が原料の入手の容
易さ等から好適である。Generally, industrially, mono-substituted substituents selected from the above substituents are most widely used, but di-substituted ones are particularly suitable for one type of substituents selected from the above-mentioned substituents and di-substituents. Halogen atoms, alkyl groups, alkoxy groups, hydroxy groups, etc. are industrially suitable, and substituents as trisubstitutes include halogen atoms, alkyl groups, alkoxy Bases and the like are preferred from the viewpoint of easy availability of raw materials.
前記一般式中のX、Y、Zで示されるハロゲン原子は、
特に限定されずF、O2,Br、Iが使用できるが特に
F 、OL 、 Brが好適である。また前記一般式中
X、Y、Zで示されるアルキル基及びアルコキシ基の脂
肪族飽和炭化水素残基は特に限定されず使用できるが、
一般には炭素原子数1〜4のもの、即ちメチル基、エチ
ル基、プロピル基、ブチル基、メトキシ基、エトキシ基
、プロポキシ基、ブトキシ基婢が好適に使用される。ま
た前記一般式中Xで示される、アルキルチオ基、アルコ
キシカルボニル基、ジ(アルキル)アミノ基の脂肪族飽
和炭化水素残基は、特に限定されず使用できるが、一般
には炭素原子数1〜4のものが好適である。即ち、メチ
ルチオ基、エチルチオ基、プロピルチオ基、ブチルチオ
基、メトキシカルボニル基、エトキシカルボニル基、プ
ロポキシカルボニル基、ブトキシカルボニル基、ジ(メ
チル)アミン基、ジ(エチル)アミノ基、ジ(プロピル
)アミノ基、ジ(ブチル)アミン基等が好適に使用され
る。The halogen atoms represented by X, Y, and Z in the general formula are:
Although F, O2, Br, and I can be used without particular limitation, F, OL, and Br are particularly preferred. In addition, the aliphatic saturated hydrocarbon residues of the alkyl groups and alkoxy groups represented by X, Y, and Z in the general formula are not particularly limited, but can be used,
Generally, those having 1 to 4 carbon atoms, ie, methyl group, ethyl group, propyl group, butyl group, methoxy group, ethoxy group, propoxy group, and butoxy group, are preferably used. In addition, the aliphatic saturated hydrocarbon residue represented by Preferably. That is, methylthio group, ethylthio group, propylthio group, butylthio group, methoxycarbonyl group, ethoxycarbonyl group, propoxycarbonyl group, butoxycarbonyl group, di(methyl)amine group, di(ethyl)amino group, di(propyl)amino group , di(butyl)amine group, etc. are preferably used.
また前記一般式中Xで示されるカルボキシル基の塩型基
及びスルホン酸基の塩型基は一般的に−aooeMe
及ヒ−5o3en”テ表b サti、、−トシテは特に
限定されるものではないが一般にはアンモニウム(NH
4e);ナトリウム(Nae)、カリウム(KO)、リ
チウム(Lte)等のアルカリ金属;マグネシウム(1
/2 Mg”)、カルシウム(1/2ca’e)等のア
ルカリ土類金属等が最も好適に使用される。Furthermore, the carboxyl group salt type group and the sulfonic acid group salt type group represented by X in the general formula are generally -aooeMe
Although there are no particular limitations on the content, it is generally ammonium (NH).
4e); Alkali metals such as sodium (Nae), potassium (KO), lithium (Lte); magnesium (1
Alkaline earth metals such as calcium (1/2 Mg") and calcium (1/2 ca'e) are most preferably used.
更に前記一般式中のXで示されるビス(ハロアルキル)
アミノ基は一般的に(X’(Oa2) )zNで表わさ
れ、x′で示されるハロゲン原子は塩素、臭素、沃素、
及び弗素の各原子が特に限定されず用いられ、またmは
1〜4の整数で表わされるものが最も好適に使用される
。Furthermore, bis(haloalkyl) represented by X in the above general formula
The amino group is generally represented by (X'(Oa2))zN, and the halogen atom represented by x' is chlorine, bromine, iodine,
and fluorine atoms are used without particular limitation, and m is most preferably an integer of 1 to 4.
前記一般式で示される有機ゲルマニウム化合物は、常温
常圧に於いては一般に無色透明、淡黄色、黄色又はかっ
色の液体若しくは固体であり、蒸留若しくはカラムクロ
マトグラフィーを用いて精製することができる。また該
有機ゲルマニウム化合物は一般的には水には難溶である
が、ヘキサン、ベンゼン尋はとんどすべての有機溶媒に
は可溶である。また酸性あるいはアルカリ性水溶液中忙
於いてはその濃度および温度によって安定性は異なるが
、一般に炭素−窒素2重結合が加水分解を受け、アミノ
アルキル(トリアルキル)ゲルマニウムと対応するカル
ボニル化合物(例えば置換ベンズアルデヒド又は置換ア
セトアルデヒドなど)K分解する傾向にある。The organic germanium compound represented by the above general formula is generally a colorless transparent, pale yellow, yellow, or brown liquid or solid at normal temperature and pressure, and can be purified using distillation or column chromatography. Furthermore, the organic germanium compound is generally sparingly soluble in water, but hexane and benzene are soluble in almost all organic solvents. In addition, in acidic or alkaline aqueous solutions, the stability varies depending on the concentration and temperature, but in general, the carbon-nitrogen double bond undergoes hydrolysis, and aminoalkyl (trialkyl) germanium and the corresponding carbonyl compound (such as substituted benzaldehyde or Substituted acetaldehydes, etc.) tend to undergo K decomposition.
該有機ゲルマニウム化合物が前記一般式で示される化学
構造を有することは、一般に次の(イ)〜に)の手段に
よって確認、同定することができる。The fact that the organic germanium compound has the chemical structure represented by the above general formula can generally be confirmed and identified by the following methods (a) to (b).
(イ)赤外吸収スペクトル(1r)を測定することKよ
り、有機ゲルマニウム化合物の分子内に存在する特徴的
な化学結合及び官能基の糧類を確認することができる。(a) By measuring the infrared absorption spectrum (1r), it is possible to confirm the characteristic chemical bonds and functional groups present in the molecule of the organic germanium compound.
例えば、該有機ゲルマニウム化合物は、1/、4 Q儂
−”付近に1
−O=N−結合に基づく特徴的な吸収を示す◎←) 質
量スペクトル< ms > を測定し、観察される各ピ
ーク(一般にはイオンの質11mを荷電数eで割ったm
/eで表わされる値)K相当する組成式を算出すること
により、測定に供した試料の結合様式更に終局的にはそ
の分子量を推定することができる。即ち、測定に供した
試料を一般式
で表した場合、一般に分子量に相当する分子イオンピー
ク(Mo)は観測され難いが、分子イオンピークからR
が脱離したMo−Rに相当O■
するピーク、R3Go、R2Go 、 ’fC相当する
ピーク等が現われる。For example, the organic germanium compound exhibits a characteristic absorption based on the 1-O=N- bond in the vicinity of 1/4Q ◎←) Mass spectrum <ms> is measured, and each peak observed (Generally, the quality of the ion, 11m, is divided by the number of charges, m
/e) By calculating the corresponding compositional formula, it is possible to estimate the binding mode and ultimately the molecular weight of the sample subjected to measurement. That is, when a sample subjected to measurement is expressed by a general formula, it is generally difficult to observe a molecular ion peak (Mo) corresponding to the molecular weight, but from the molecular ion peak R
A peak corresponding to Mo-R desorbed from O, a peak corresponding to R3Go, R2Go, 'fC, etc. appear.
更に1ゲルマニウム原子を含有するピークは、同位体の
多いゲルマニウム原子を含有する化合物に特徴的な様相
を呈する。Furthermore, the peak containing one germanium atom exhibits a characteristic feature of a compound containing a germanium atom with many isotopes.
(ハ)+3□−核磁気共鳴スペクトル(180−nmr
)を測定することにより、該有機ゲルマニウム化合物
中の炭素原子の個数、炭素鎖の配列様式、及び炭素原子
の結合様式を知ることができる。(c) +3□-nuclear magnetic resonance spectrum (180-nmr
), it is possible to know the number of carbon atoms, the arrangement of carbon chains, and the bonding mode of carbon atoms in the organic germanium compound.
代表例として、前記一般式中、Rがエチル基、Aが水素
原子、nが3、Xが臭素原子、!及び2が水素原子であ
るゲルマニウム化合物の”O−nmrに現われるピーク
の化学シフト値(テトラメチルシラン基準、δ、ppm
)解析結果を示すと以下のようになる。As a representative example, in the above general formula, R is an ethyl group, A is a hydrogen atom, n is 3, and X is a bromine atom. and the chemical shift value of the peak appearing in O-nmr of a germanium compound in which 2 is a hydrogen atom (tetramethylsilane standard, δ, ppm
) The analysis results are as follows.
に)元素分析によって炭素、水素、窒素、イオウ原子、
ハロゲン原子、及びゲルマニウムの各重量%をめ、更に
認知された各元素の重量%の和を100から減じること
により、酸素の重量%を算出することができ、したがっ
て測定に供した有機ゲルマニウム化合物の組成式を決定
することができる。) Carbon, hydrogen, nitrogen, sulfur atoms, by elemental analysis
The weight percent of oxygen can be calculated by adding the weight percent of halogen atoms and germanium, and subtracting the sum of the weight percent of each recognized element from 100, and therefore the weight percent of the organogermanium compound subjected to measurement. The compositional formula can be determined.
本発明の有機ゲルマニウム化合物の製造方法は特に限定
されずいかなる方法で得られたものでもよい。一般に好
適に用いられる代表的な製造方法を下記に示す。即ち、
一般式
%式%
(但し、Rはアルキル基、nは正の整数である。)
で示されるアミノアルキル(トリアルキル)ゲルマニウ
ム化合物と、一般式
(但し、Aは水素原子又はアルキル基、1%”N2は水
素原子、アルキル基、アルコキシ基、ヒドロキシ基、シ
アン基、ニトロ基、アルキルチオ基、アルコキシカルボ
ニル基、カルボキシル基及びその塩型基、スルホン酸基
及びその塩型基、ジ(アルキル)アミノ基、又はジ(ハ
ロアルキル)アミン基で、X及びIは隣接した炭素原子
に置換しCで表わされる一基であってもよい。)
で示される置換ベンズアルデヒド又は置換フェニルアル
キルケト/とを脱水縮合させることKより、高収率で目
的″とする本発明の有機ゲルマニウム化合物を得ること
ができる。The method for producing the organic germanium compound of the present invention is not particularly limited, and any method may be used. Typical manufacturing methods that are generally suitably used are shown below. That is,
An aminoalkyl (trialkyl) germanium compound represented by the general formula % formula % (wherein R is an alkyl group and n is a positive integer) and a general formula (wherein A is a hydrogen atom or an alkyl group, 1% "N2 is a hydrogen atom, an alkyl group, an alkoxy group, a hydroxy group, a cyan group, a nitro group, an alkylthio group, an alkoxycarbonyl group, a carboxyl group and its salt type group, a sulfonic acid group and its salt type group, di(alkyl)amino or a di(haloalkyl)amine group, in which X and I are substituted on adjacent carbon atoms and may be a single group represented by C.) By doing this, the desired organic germanium compound of the present invention can be obtained in high yield.
上記反応の仕込みモル比は特に限定されるものではない
が、通常郷モルで行なうのが望ましい。また上記反応に
は反応溶媒を使用するのが好ましく、例えばベンゼン、
トルエン、エタノール、クロロホルム等の水と共沸する
溶媒が好適に使用される。反応温度は例えば−20℃〜
150℃で行なうことができるが、好適とする温度範囲
で行なうのが好ましい。また反応時間は反応温度によっ
て異なるが、一般には数分から数日の間で選べばよい。The molar ratio of charges in the above reaction is not particularly limited, but it is usually desirable to carry out the molar ratio. In addition, it is preferable to use a reaction solvent in the above reaction, such as benzene,
Solvents that are azeotropic with water, such as toluene, ethanol, and chloroform, are preferably used. The reaction temperature is, for example, -20℃~
Although it can be carried out at 150°C, it is preferably carried out within a suitable temperature range. Although the reaction time varies depending on the reaction temperature, it can generally be selected from several minutes to several days.
上記反応の脱水縮合反応を促進するために反応系に酢酸
、蟻酸等の酸又はBF3・r;t2o 等を添加する手
段はしばしば好適に用いられる。また、脱水剤として塩
化カルシウム、モレキュラーシープ等を反応系内に添加
する方法も有効な手段となる◎
本発明の有機ゲルマニウム化合物は新規化合物であり、
本発明者等が該化合物について生理活性試験を行なった
ところ、特に制癌作用が著しいことを確認した。即ち、
該ゲルマニウム化合物は後述する実施例に示すごとく、
マウスに於けるエールリッヒ腹水癌に対し優れた制癌効
果を発揮する。In order to promote the dehydration condensation reaction of the above reaction, a means of adding an acid such as acetic acid, formic acid, or BF3.r;t2o to the reaction system is often suitably used. In addition, adding calcium chloride, molecular sheep, etc. as a dehydrating agent into the reaction system is also an effective method.◎ The organic germanium compound of the present invention is a new compound,
When the present inventors conducted a physiological activity test on the compound, it was confirmed that it has a particularly remarkable anticancer effect. That is,
As shown in the examples below, the germanium compound is
It exhibits excellent anticancer effects against Ehrlich ascites carcinoma in mice.
即ち、本発明の有機ゲルマニウム化合物は制癌剤として
各種癌の予防、治療又は処理のために利用できる極めて
有用な化合物である。That is, the organic germanium compound of the present invention is an extremely useful compound that can be used as an anticancer agent for the prevention, treatment, or treatment of various cancers.
本発明の有機ゲルマニウム化合物を制癌剤として用いる
ときは経口、非経口(たとえば腹腔内、直腸内)または
局所投与のいずれKよっても患者に投与することができ
、その際の有効成分である有機ゲルマニウム化合物の有
効投与量は、投与すべき患者の年令、体重、症状の軽重
、癌の種類等に応じて異なるが、一般には800〜o、
o 02 my/Ky/日、好ましくは500〜0゜0
111g/ Kp 7日とすることができる。該1日の
投与量は1日1回のみ又は1日数回(3〜5回)K分げ
て投与することができる。また、上記の投与量は単なる
指針であり、処置を行なう医師の判断により、上記範囲
を越えて投与することも可能であることはいうまでもな
い。When the organic germanium compound of the present invention is used as an anticancer agent, it can be administered to a patient either orally, parenterally (for example, intraperitoneally or rectally), or locally. The effective dose varies depending on the age, weight, severity of symptoms, type of cancer, etc. of the patient to whom it is administered, but generally it is 800 to 800 o,
o 02 my/Ky/day, preferably 500-0°0
It can be 111g/Kp 7 days. The daily dose can be administered only once a day or divided into several times (3 to 5 times) a day. It goes without saying that the above-mentioned dosage is merely a guideline, and it is possible to administer doses exceeding the above-mentioned range at the discretion of the treating physician.
上記有効成分の投与に当って、上記有機ゲルマニウム化
合物は、希望とする投与方法(経口、非経口又は局所)
K応じて、穫々の剤形に製剤することができる。When administering the above-mentioned active ingredient, the above-mentioned organic germanium compound should be administered according to the desired administration method (oral, parenteral or topical).
Depending on the K, various dosage forms can be formulated.
例えば、経口投与に際しては、シロップ、カプセル剤等
の剤形に製剤することができ、また、非経口投与に際し
ては、懸濁液、生薬等の剤形に製剤することができ、さ
らに局所投与に際しては、軟膏、硬膏、クリーム等の剤
形に製剤することができる。For example, for oral administration, it can be formulated into syrups, capsules, etc., for parenteral administration, it can be formulated into suspensions, crude drugs, etc., and for topical administration, it can be formulated into dosage forms such as suspensions and crude drugs. can be formulated into dosage forms such as ointments, plasters, and creams.
これら製剤中における有効成分の濃度は特に制限される
ものではなく、剤形に応じて広範に変えることができる
が、一般には0.05〜90重量%、好ましくは1〜6
0重1%程度の濃度とすることができる。The concentration of the active ingredient in these preparations is not particularly limited and can vary widely depending on the dosage form, but is generally 0.05 to 90% by weight, preferably 1 to 6% by weight.
The concentration can be about 0% by weight.
上記製剤に使用しうる賦形剤としては当該分野で常用さ
れているものはいずれも使用可能であり、液体形態の製
剤に対しては、例えば生理食塩水、界面活性剤液、ぶど
う糖液、アルコール、エステル類等が挙げられる。As excipients that can be used in the above preparations, any excipient commonly used in the field can be used; for liquid preparations, for example, physiological saline, surfactant solution, glucose solution, alcohol , esters, etc.
かかる製剤の具体例を示せば次のとおりである。Specific examples of such formulations are as follows.
製造例1:カプセル剤
ステアリン酸マグネシウム0.6重量部に乳糖4.5重
量部を加えて攪拌混合することKより均一とし、さらに
乳糖5重量部と結晶セルロース10重皺部を加えて混合
する。この混合物に有機ゲルマニウム化合物20重量部
を加えて、再度混合することKより調製液を得る。この
液をゼラチンカプセルに充填することKよりカプセル剤
を製造するとよい。Production Example 1: Capsule Add 4.5 parts by weight of lactose to 0.6 parts by weight of magnesium stearate, stir and mix to make the mixture more uniform, then add 5 parts by weight of lactose and 10 parts by weight of crystalline cellulose and mix. . Add 20 parts by weight of an organic germanium compound to this mixture and mix again to obtain a prepared liquid. Capsules may be prepared by filling this liquid into gelatin capsules.
製造例2:軟こう剤
ステアリルアルコール10重量部、流動パラフィン20
重量部およびワセリン160重量部を80℃に加温溶解
した後、コレステO−ルQ。Production example 2: Softener stearyl alcohol 10 parts by weight, liquid paraffin 20 parts by weight
After heating and dissolving 160 parts by weight of vaseline at 80°C, Cholesteel O-Q was obtained.
5重量部ならびに有機ゲルマニウム化合物10重量部を
よく攪拌しながら加え、さらKよく攪拌を行った後室温
に放置し、適当な硬さにして軟こう剤を得るとよい。5 parts by weight and 10 parts by weight of the organic germanium compound are added with thorough stirring, and after further stirring, the mixture is allowed to stand at room temperature to obtain an appropriate hardness to obtain a softener.
本発明を更に具体的に説明するため、以下実施例を挙げ
て説明するが、本発明はこれらの実施例に限定されるも
のではない。EXAMPLES In order to explain the present invention more specifically, examples will be described below, but the present invention is not limited to these examples.
実施例 1゜
r−アミノプロピルトリエチルゲルマニウム(3,78
JF)、p−ブロモベンズアルデヒド(3,40t)、
及びベンゼン(30st/)の混合物を油浴上で2時間
加熱還流することKまり共沸脱水を行なった。低沸点成
分を除去した後、残渣を真空蒸留して、沸点15’ O
℃/ 0.15 ff17iHgの淡黄色透明液体(/
i、22JF)を得た。Example 1゜r-aminopropyltriethylgermanium (3,78
JF), p-bromobenzaldehyde (3,40t),
Azeotropic dehydration was performed by heating and refluxing a mixture of benzene and benzene (30st/) for 2 hours on an oil bath. After removing the low-boiling components, the residue is vacuum distilled to a boiling point of 15'O
℃/0.15ff17iHg pale yellow transparent liquid (/
i, 22JF) was obtained.
該化合物の赤外吸収スペクトルを測定したところ、添付
図面第1図に示す通り、2950〜2800 crn−
’にa−i結合に基づく吸収、1640儂−’Kcn=
a結合に基づく吸収、及び1590cWL−” 、14
80 cIIL−’ KヘンセyllK基ツく吸収が認
められた。When the infrared absorption spectrum of the compound was measured, as shown in Figure 1 of the attached drawings, it was 2950-2800 crn-
Absorption based on the a-i bond in ', 1640 儂-'Kcn=
Absorption based on a bond, and 1590cWL-”, 14
80 cIIL-'K-based absorption was observed.
質量スペクトルを測定したところ、I!I/e356に
一−0@H5に対応するピーク、m/e 161K(0
1Ej )3 Ge” K対応するピーク等が観測され
た。When the mass spectrum was measured, I! Peak corresponding to I/e 356-0@H5, m/e 161K (0
1Ej)3Ge''K-corresponding peaks were observed.
1m()−核磁気共鳴スペクトル(テトラメチルシラン
基準、δppm )を測定し、得られたスペクトルの各
ピークの化学シフト値を解析したところ、次の通りであ
った。A 1m()-nuclear magnetic resonance spectrum (tetramethylsilane standard, δppm) was measured, and the chemical shift values of each peak in the obtained spectrum were analyzed, and the results were as follows.
(129,9)(152,03
元素分析を行なったところ、049.87%、H6,8
9%、N3.79%、Br20.50%、Ge18.9
6%なる値を示し組成式Of、8 TIHN nr G
e(384,91)としての計算値であるo49,92
%、116.82%、MS、64%、Br2Q、76%
、Ge18.86%に一致した。(129,9) (152,03 Elemental analysis revealed 049.87%, H6,8
9%, N3.79%, Br20.50%, Ge18.9
It shows a value of 6% and the composition formula Of, 8 TIHN nr G
o49,92 which is the calculated value as e(384,91)
%, 116.82%, MS, 64%, Br2Q, 76%
, Ge18.86%.
以上の結果から、生成物が下記構造式で示されるa−(
p−ブロモフェニルメチリデン)−ァーアミノプ四ピル
トリエチルゲルマニウムであることが明らかとなった。From the above results, the product is a-(
It was revealed that the product was p-bromophenylmethylidene)-aminoptetrapyrutriethylgermanium.
実施例 λ
δ−アミノブチルトリエチルゲルマニウム(1,21t
)、2.4− シpロロペンズアルデヒド(o、91
#)、及びクロロホルム(20sl)の混合物を油浴上
で3時間加熱還流するととKより共沸脱水を行なった。Example λ δ-aminobutyltriethylgermanium (1,21t
), 2.4-ciprolopenzaldehyde (o, 91
#) and chloroform (20 sl) was heated under reflux on an oil bath for 3 hours to perform azeotropic dehydration from K.
低沸点成分を除去した後、残渣を真空蒸留して、沸点1
60℃10.1WLWL Ilgの無色透明液体(1,
44#)を得た。After removing low boiling point components, the residue is vacuum distilled to reduce the boiling point to 1.
60℃10.1WLWL Ilg colorless transparent liquid (1,
44#) was obtained.
該化合物の赤外吸収スペクトルを測定したところ、29
50〜2800CII−’ にO−H結合に基づく吸収
、1650 cm+−11c ca=y 結合に基づく
吸収、及び1580.146011!III=1にベン
ゼン環に基づく吸収が認められた。When the infrared absorption spectrum of the compound was measured, it was found that 29
Absorption based on O-H bond at 50-2800 CII-', absorption based on 1650 cm+-11c ca=y bond, and 1580.146011! Absorption based on the benzene ring was observed at III=1.
質量スペクトルを測定したところ、m/* 3 ?OK
分子イオン(Me) K対応するピーク、m/e360
に−−t4H6に対応するピーク等が観測された。When the mass spectrum was measured, m/*3? OK
Molecular ion (Me) K corresponding peak, m/e360
- Peaks corresponding to t4H6 were observed.
1m(3−核磁気共鳴スペクトル(テトラメチルシラン
基準、δ、ppff’)を測定し、得られたスペクトル
の各ピークの化学シフト値を解析したところ、次の通り
であった。1m (3-nuclear magnetic resonance spectrum (tetramethylsilane standard, δ, ppff') was measured, and the chemical shift values of each peak in the obtained spectrum were analyzed, and the results were as follows.
t
a (13Z4)、 b (135,6)、 c (1
29,6)a (136,7)、 e (127,5)
、 r (129,6)元素分析を行なったところ、0
52.47%、H7″:7%、N3.54%、0t18
.01%、G519.10%なる値を示し、組成式
%式%
以上の結果から、生成物が下記構造式で示さレルN −
(2,4−ジクロロフェニルメチリゾ/)−δ−アミノ
ブチルトリエチルゲルマニウムであることが明らかとな
った。t a (13Z4), b (135,6), c (1
29,6) a (136,7), e (127,5)
, r (129,6) elemental analysis revealed that 0
52.47%, H7″: 7%, N3.54%, 0t18
.. 01%, G519.10%, and the compositional formula % formula % From the above results, the product is shown by the following structural formula.
It became clear that it was (2,4-dichlorophenylmethyliso/)-δ-aminobutyltriethylgermanium.
L
実施例 五
アーアミノプ四ピルトリエチルゲルマニウム(3,06
#)、p−クロロアセトフェノン(2゜02t)、及び
ベンゼン(5[1mg)の混合物KBIF、−エーテラ
ート(3滴)を加え、油浴上で6時間加熱還流すること
Kより共沸脱水を行なった。低沸点成分を除去した後、
残液を真空蒸留して、沸点144℃/ 0.05 WL
m Hgの淡黄色粘稠液体(3,09#)を得た。L Example Penta-aminoptetrapyrutriethylgermanium (3,06
Add KBIF, -etherate (3 drops), a mixture of p-chloroacetophenone (2°02t), and benzene (5 [1mg)], and heat under reflux on an oil bath for 6 hours to perform azeotropic dehydration. Ta. After removing low boiling point components,
Vacuum distillation of the residual liquid yields a boiling point of 144°C/0.05 WL
A pale yellow viscous liquid (3,09#) of m Hg was obtained.
該化合物の赤外吸収スペクトルを測定したところ、29
50〜2800傭−8に0−H結合に基づく吸収、16
30 CIL−’ に0H=N結合に基づく吸収等が認
められた。When the infrared absorption spectrum of the compound was measured, it was found that 29
Absorption based on 0-H bond at 50-2800m-8, 16
Absorption based on 0H=N bond was observed in 30 CIL-'.
質量スペクトルを測定したところ、m/@ 526に一
−OlH5ic対応するピーク、m/e 268K M
”−(Ox Hlt)s に対応するピーク等が観測さ
れた0
+AC−核磁気共鳴スベクトル(テトラメチルシラン基
準)δ5P1)II)を測定し、得られたスペクトルの
各ピークの化学シフト値を解析したところ、次の通りで
あった。When the mass spectrum was measured, a peak corresponding to -OlH5ic at m/@526, m/e 268K M
The 0+AC-nuclear magnetic resonance vector (tetramethylsilane standard) δ5P1)II) in which peaks corresponding to ``-(Ox Hlt)s were observed was measured, and the chemical shift value of each peak in the obtained spectrum was calculated. The analysis revealed the following.
元素分析を行なったところ、o57.23%、H7,8
5X、 N 5.95%、0t10.5596’、G。Elemental analysis revealed o57.23%, H7.8
5X, N 5.95%, 0t10.5596', G.
20.75%なる値を示し組成式C!17 H2B k
l OtG@(354,45)としての計算値である0
57.59X、17.98%、N5.95%、0L10
.0O%、Go 20.48 XK一致した。It shows a value of 20.75% and the composition formula C! 17 H2B k
0 which is the calculated value as l OtG@(354,45)
57.59X, 17.98%, N5.95%, 0L10
.. 00%, Go 20.48 XK matched.
以上の結果から、生成物が下記構造式で示されるN−(
1−(1)−クロロフェニルエチリデン)〕−〕r−ア
ミノプロピルトリエチルゲルマニウであることが明らか
となった。From the above results, the product is N-(
It became clear that it was 1-(1)-chlorophenylethylidene)]-]r-aminopropyltriethylgermanium.
B3
実施例 4゜
実施例1〜3に記載した方法と同様にして種々の有機ゲ
ルマニウム化合物を合成した。下記式で示される該生成
物の構造式中の置換基R1A、X、Y、Zの種類及びn
の値、並びに核化合物の様態、赤外吸収スペクトルにお
ける特性吸収値、11□−核磁気共鳴スペクトルにおけ
る化学シフト値(但し、メチレン基の値はほば同一の値
を示すので省略した)、及び元素分析値を第1表に記載
した。B3 Example 4 Various organic germanium compounds were synthesized in the same manner as in Examples 1 to 3. Types of substituents R1A, X, Y, Z and n in the structural formula of the product represented by the following formula
value, as well as the aspect of the nuclear compound, the characteristic absorption value in the infrared absorption spectrum, the chemical shift value in the 11□-nuclear magnetic resonance spectrum (however, the value of the methylene group is omitted because it shows almost the same value), and Elemental analysis values are listed in Table 1.
実施例 5゜
実施例1で合成した有機ゲルマニウム化合物を用いてマ
ウスのエールリッヒ腹水癌に対する制癌活性を試験した
。Example 5 The organogermanium compound synthesized in Example 1 was tested for anticancer activity against Ehrlich's ascites carcinoma in mice.
該ゲルマニウム化合物の規定量を、少量のジメチルスル
ホキシドを添加した界面活性剤ツイーン80を含む生理
食塩水(o、as#)に懸濁させて試料溶液を調整した
。該試料溶液を、エールリクヒ癌細胞lX10’個を有
するO D Fl系マウス(雌)6匹の腹腔内に0.5
dづつ9日間連続注射投与した。その60日間にわたる
延命効果試験の結果から、平均生存日数(MST)をめ
、対照群(30匹)の平均生存日数と比較することによ
りT/C+ (%)を算出した。結果を第2表に記載し
た。A sample solution was prepared by suspending a specified amount of the germanium compound in physiological saline (o, as#) containing surfactant Tween 80 to which a small amount of dimethyl sulfoxide was added. The sample solution was intraperitoneally administered into 6 O D Fl mice (female) containing 1×10' Ehrlich cancer cells.
Administered by continuous injection for 9 days. From the results of the 60-day survival effect test, the mean survival days (MST) was determined and T/C+ (%) was calculated by comparing it with the mean survival days of the control group (30 animals). The results are listed in Table 2.
実施例 6゜
実施例2.3及び4で合成した有機ゲルマニウム化合物
を用い、実施例5と同様な方法でマウスのエールリッヒ
腹水癌に対する制癌活性を試験した。その結果を第3表
に記載した。Example 6 Using the organic germanium compounds synthesized in Examples 2.3 and 4, the anticancer activity against Ehrlich's ascites carcinoma in mice was tested in the same manner as in Example 5. The results are listed in Table 3.
’:j T ”、臼
第 3 表
実施例 l
実施例1〜3に記載した方法と同様にして種々の有機ゲ
ルマニウム化合物を合成し、実施例5と同様な方法にて
マウスのエールリッヒ腹水癌に対する制癌活性を試験し
た。核化合物の構造式、元素分析値、及び制癌活性結果
を第4表に記載した。':j T'', Mortar Table 3 Example 1 Various organic germanium compounds were synthesized in the same manner as described in Examples 1 to 3, and the results were shown to be effective against Ehrlich ascites carcinoma in mice in the same manner as in Example 5. The anticancer activity was tested. The structural formula, elemental analysis values, and anticancer activity results of the core compound are listed in Table 4.
X1゛・橿1)X1゛・桿1)
添付図面第1図は、実施例1で得られたN−(p−ブロ
モフェニルメチリデン)−γ−アミノプロピルトリエチ
ルゲルマニウムの赤外吸収スペクトルのチャートである
。
特許出願人
徳山曹達株式会社FIG. 1 of the accompanying drawings is a chart of the infrared absorption spectrum of N-(p-bromophenylmethylidene)-γ-aminopropyltriethylgermanium obtained in Example 1. Patent applicant Tokuyama Soda Co., Ltd.
Claims (1)
種又は異種の水素原子、ノ・ロゲン原子、アルキル基、
アルコキシ基、ヒト四キシ基、シアノ基、二) a基、
アルキルチオ基、アルコキシカルボニル基、カルボキシ
ル基及びその塩型基、スルホン酸基及びその塩型基、ジ
(アルキル)アミノ基、又はジ()−ロアルキル)アミ
ン基で、X及びIは隣接した炭素もよい。) で示される有機ゲルマニウム化合物。 (但し、Rはアルキル基;nは正の整数;Aは水素原子
又はアルキル基:z、、x及び2はそれぞれ同種又は異
種の水素原子、ハ、ロゲン原子、アルキル基、アルコキ
シ基、ヒト四キシ基、シアノ基、ニトロ基、アルキルチ
オ基、アルコキシカルボニル基、カルボキシル基及びそ
の塩型基、スルホン酸基及びその塩型基、ジ(アルキル
)アミノ基、又はジ(ハロアルキル)アミノ基でX及び
!は隣接した炭素原よい。) で示される有機ゲルマニウム化合物を有効成分とする制
癌剤。[Claims] is a hydrogen atom or an alkyl group: X,! and 2 are the same or different hydrogen atoms, hydrogen atoms, alkyl groups,
Alkoxy group, human tetraxy group, cyano group, 2) a group,
An alkylthio group, an alkoxycarbonyl group, a carboxyl group and its salt type group, a sulfonic acid group and its salt type group, a di(alkyl)amino group, or a di()-roalkyl)amine group, where X and I also include adjacent carbon atoms. good. ) An organic germanium compound represented by (However, R is an alkyl group; n is a positive integer; A is a hydrogen atom or an alkyl group; z, , x and 2 are the same or different hydrogen atoms, ha, a rogen atom, an alkyl group, an alkoxy group, a human X and An anticancer agent containing an organic germanium compound as an active ingredient.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP59083831A JPS60228490A (en) | 1984-04-27 | 1984-04-27 | Organogermanium compound |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP59083831A JPS60228490A (en) | 1984-04-27 | 1984-04-27 | Organogermanium compound |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS60228490A true JPS60228490A (en) | 1985-11-13 |
JPH0144195B2 JPH0144195B2 (en) | 1989-09-26 |
Family
ID=13813639
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP59083831A Granted JPS60228490A (en) | 1984-04-27 | 1984-04-27 | Organogermanium compound |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS60228490A (en) |
-
1984
- 1984-04-27 JP JP59083831A patent/JPS60228490A/en active Granted
Also Published As
Publication number | Publication date |
---|---|
JPH0144195B2 (en) | 1989-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5366997A (en) | Oxygen substituted derivatives of nucleophile-nitric oxide adducts as nitric oxide donor prodrugs | |
JPS6089474A (en) | Morphinan derivative, production thereof and antitumor agent containing said compound | |
US20210032270A1 (en) | Biaryl derivative, preparation method thereof and pharmaceutical application thereof | |
JPH07509726A (en) | Pyrrolopyrimidines as CRF antagonists | |
WO2013082150A1 (en) | Small molecule inhibitors of nicotinamide phosphoribosyltransferase (nampt) | |
MXPA97003634A (en) | Derivatives of antibacterial benzymidazole | |
WO2009100014A1 (en) | System for fluorinating organic compounds | |
JPS60228490A (en) | Organogermanium compound | |
US9382267B2 (en) | Small molecule inhibitors of nicotinamide phosphoribosyltransferase (NAMPT) | |
KR20230074722A (en) | Pyrazole boronic acid compounds, pharmaceutical compositions containing them, and uses thereof | |
KATO et al. | Studies on Ketene and Its Derivatives. LIV. Reaction of Diketene with Ketene Acetals | |
Pine et al. | Base-promoted rearrangements of. alpha.-arylneopentylammonium salts | |
JPH057391B2 (en) | ||
JPS61191667A (en) | Urea compound | |
EP3301100A1 (en) | Organometallic fluconazole derivates and their use as antimycotics | |
CN109734682B (en) | Cyclic alkenylimine medical intermediate, preparation method and application thereof as medicament for inhibiting growth of cancer cells | |
JPH0144194B2 (en) | ||
JPS6322069A (en) | Heterocyclic aromatic compound | |
JPH0370700B2 (en) | ||
KR102406248B1 (en) | 1,2,3-Triazole Derivative Compounds as HSP90 Inhibitor | |
Al-Rubaay | Metal-Catalysed Electrophilic Ring Closing Strategies to Organic Heterocycles | |
JPS63230670A (en) | Substituted pyridiylacetic acid derivative | |
JPS62221692A (en) | Silatrane compound | |
JPS62226989A (en) | Silatrane compound | |
JPH0326699B2 (en) |